25Jun 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Brepocitinib, a TYK2/JAK1 inhibitor, shows promise in treating psoriatic arthritis (PsA). A phase IIb study evaluated the efficacy and safety of oral brepocitinib in participants with moderately to severely active PsA over 52 weeks. At week 16, the brepocitinib groups exhibited significantly higher response rates, including a 20% improvement in disease activity (ACR20), ACR50/ACR70 response rates, PASI75/PASI90 improvement in psoriasis, and minimal disease activity.

  • #rheumatology

Like

Save

Share